Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

| More on:
One girl leapfrogs over her friend's back.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Ltd (ASX: PME) share price has been an incredible performer for shareholders in the past 12 months, up 134%!

Created with Highcharts 11.4.3Pro Medicus PriceZoom1M3M6MYTD1Y5Y10YALL18 Nov 202318 Nov 2024Zoom ▾Jan '24Mar '24May '24Jul '24Sep '24Nov '24Jan '24Jan '24Apr '24Apr '24Jul '24Jul '24Oct '24Oct '24www.fool.com.au

The impressive business has seen its earnings rise, and the price-earnings (P/E) ratio has continued to climb.

How far could the healthcare tech company rise?

One broker thinks there's still plenty of room left in the business' valuation for further gains in the next year. The ASX share is certainly delivering enough earnings growth to excite investors.

Price target on Pro Medicus shares

Broker analysts regularly scan the market for opportunities, and they'll use a price target to indicate whether they think a business is overvalued or undervalued.

A price target is where the analysts think the share price will be in 12 months following the investment call. Of course, they don't have crystal balls. They're giving their rating based on the company's operational progress, wider economic conditions and so on.

The broker Wilsons is very optimistic on where Pro Medicus shares can go from here. Wilsons recently decided to crank up its price target on Pro Medicus shares by 76% to $255. That implies the Pro Medicus share price could rise by a further 24%.

Unsurprisingly, Wilsons has an overweight rating on Pro Medicus, which means it's optimistic about the ASX healthcare company.

Why is the ASX healthcare share doing so well?

The company has reported a number of positives in the last few months and the last few years.

Its financial performance has been utterly impressive, with the latest result showing the strength of its business model.

In the FY24 result for the 12 months to 30 June 2024, Pro Medicus reported revenue growth of 29.3% to $161.5 million, underlying operating profit (EBIT) of $112.3 million, up 33.8%, and net profit after tax (NPAT) growth of 36.5% to $82.8 million. This helped fund a 33.3% increase in the final dividend to 22 cents per share.

Incredibly, the EBIT margin was 69.5% in FY24, making it one of the most profitable operating companies in Australia.

While Pro Medicus has been successful at winning new clients, a recent contract renewal was particularly pleasing. It revealed an eight-year contract renewal with US-based Mercy Health for a minimum value of A$98 million.

The Mercy Health contract was renewed at an increased per transaction fee, for a longer term. This vote of confidence in Pro Medicus bodes well for its other large existing contracts and implies it could win more revenue from its customer base as contracts are renewed.

With the high profit margins of the ASX share and the ongoing revenue growth, the future looks very bright.

Should you invest $1,000 in Pro Medicus Limited right now?

Before you buy Pro Medicus Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Pro Medicus Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Six smiling health workers pose for a selfie.
Healthcare Shares

Guess how much $5,000 invested in Sigma shares in December 2023 is worth now!

Sigma shares have soared over the past year alongside the merger with Chemist Warehouse.

Read more »

Woman with headphones on relaxing and looking at her phone happily.
Healthcare Shares

Everything you need to know about the latest CSL dividend

CSL's latest dividend should be turning investors' heads...

Read more »

thoughtful investor sitting at computer
Healthcare Shares

What are brokers saying about CSL shares after the selloff?

The biotech giant's shares hit a 52-week low yesterday. Is this a buying opportunity?

Read more »

A man looking at his laptop and thinking.
Earnings Results

CSL shares push higher despite 'mixed result with headline misses'

There were positives and negatives in the company's first half performance.

Read more »

Scientists working in the laboratory and examining results.
Earnings Results

CSL share price on watch amid $2.1b half year profit and dividend hike

Let's see how this biotech giant performed during the first half of FY 2025.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 300 healthcare stock just rocketed 20% on BIG earnings growth

Investors are piling into the ASX 300 healthcare stock on Monday. But why?

Read more »

Health professional putting on gloves.
Earnings Results

Why this ASX 200 share is soaring in Monday's sinking market

The ASX 200 share is shrugging off the broader market fall today to rocket higher. But why?

Read more »

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Why is the Sigma share price soaring 6%?

Sigma has upgraded its FY25 guidance ahead of the anticipated Chemist Warehouse merger completion.

Read more »